Downregulation of S100 calcium binding protein A12 inhibits the growth of glioma cells

Chunhe Lu¹, Jia Liu¹, Mingze Yao¹, Lun Li² and Guangyu Li¹*

Abstract

Background: S100 calcium binding protein A12 (S100A12) is a member of the S100 protein family and is widely expressed in neutrophil and low expressed in lymphocytes and monocyte. However, the role of S100A12 in glioma has not yet been identified.

Methods: In the present study, we carried out immunohistochemical investigation of S100A12 in 81 glioma tissues to determine the expression of S100A12 in glioma cells, and evaluate the clinical significance of S100A12 in glioma patients. Futher we knockdown the S100A12 by shRNA, and evaluated cell proliferation, cell migration and cell apoptosis by MTT, colony formation assay, transwell assay,flow cytometry assa and western blot.

Results: We found that S100A12 was upregulated in tissues of glioma patients and the expression was correlated to WHO stage and tumor size. Further, we found that knockdown S100A12 inhibits the proliferation, migration and invasion of glioma cells through regulating cell apoptosis and EMT.

Conclusion: S100A12 plays a vital role in glioma progression, and may be an important regulatory molecule for biological behaviors of glioma cell lines.

Keywords: S100A12, Glioma, Tumor, EMT, Apoptosis
malignancies [7]. S100A12 is a member of this family and is widely expressed in neutrophil and low expressed in lymphocytes and monocyte [8]. S100A12 has also been found to be involved in multiple cancers. S100A12 is close linked to inflammation and vascular invasion and contribute to cancer metastasis [9]. It has been reported that high levels of S100A12 has been correlated with good prognosis for patients with oropharyngeal squamous cell carcinoma [10]. In addition, S100A12 was significantly increased in colorectal cancer samples when compared adjacent normal colon tissues [11]. It has been reported that the expression of S100A4 is highly correlated with the progression of glioma which indicated that S100A4 plays a vital role in the pathogenesis of glioma [12]. However, the role of S100A12 in glioma hasn’t been fully illuminated. Therefore, the aim of this study was to explore the role of S100A12 in glioma. We assumed that S100A12 was up-regulated in glioma tissues, and that knockdown of S100A12 resulted in a repression of apoptosis and a elevation of proliferation of glioma cells.

Methods

Patients and specimens
The clinical specimens were collected from glioma patients at the First Affiliated Hospital of China Medical University. Normal brain tissues were obtained from patients suffering from cerebral injury who were underwent internal decompression. Thyroid tissue from patients with thyroiditis was used as a positive control group because the protein expression of S100A12 had been well reported in thyroiditis. The patients were written consent and with the approval of the ethics committee of the China Medical University. Glioma samples were immediately fresh frozen in liquid nitrogen and then stored at −80 °C until further analysis.

Cell lines
A172, U373, U118, U251 and U87 were obtained from Chinese Academy of Sciences (Shanghai, China). The cells were cultured with Modified Eagle’s Medium (DMEM), supplemented with 10% fetal bovine serum and antibiotics (100 U/ml penicillin, 100 mg/ml streptomycin). The cell lines were incubated in 37 °C, 5% CO2 saturation.

Immunohistochemistry (IHC)
The glioma specimens and normal brain tissues were embedded in paraffin and then sliced to 4 μm sections. Rabbit polyclonal anti-S100A12 (1:200; Abcam, Cambridge, UK) and biotinylated goat anti-rabbit immunoglobulin G were used as primary and secondary antibodies. Then counterstaining with diaminobenzidine, sections were inspected under microscope.

S100A12 knockdown
The shRNA vectors were purchased from GeneChem Company (Shanghai, China). The S100A12#1 sequence was 5’-CGACTTTCAGAATTCATA-3’, the S100A12#2 sequence was 5’-GGATGCTAATCAAGATGAA-3’ and the shRNA control (shNC) sequence was 5’-TTCTCCGAACGTGTCACGT-3’. 

Cell proliferation analyses
The cell viability was determined by MTT assay. Cells were seeded on 96-well plates at 1 d, 2 d and 3d after transfection, then incubated in the medium containing 100 mg/0.1 ml of MTT (Sigma Aldrich) for 4 h and incubated at 37 °C. After removing the medium, the blue crystal layer attached to the surface of the material was dissolved using dimethyl sulfoxide (DMSO). The OD value was measured at 490 nm by enzyme immunoassay instrument.

Colony formation assay
Cells were seeded into 6 well plates at a density of 500 cells/well and cultured at 37 °C, 5% CO2 for 14 days. Cells were then fixed in 4% paraformaldehyde and stained with crystal violet solution. Colonies from 3 independent groups were counted and the data were presented as mean ± standard deviation (SD).

Cell invasion and migration assays
Transwell assay was used to evaluate the cell migration and invasion of glioma cell lines. For migration assay, 5×10^4 cells were seeded in the upper chamber with serum-free culture medium (200 μl), and the lower chamber was filled with 10% FBS medium. After culturing for 24 h, the cells were fixed with 4% paraformaldehyde and stained with gemsa for 15 min. The images were acquired under microscope and migrated cells were counted in 3 random fields. The method of invasion assay was similar to the migration analysis, while the upper chamber was coated with matrigel (BD Biosciences, San Jose, CA).

Flow cytometry assay
After 72 h of transfection, cells were collected and subjected to flow cytometry. Cell apoptosis was quantified using Annexin V-fluorescein isothiocyanate apoptosis detection kit 1 (BD Biosciences, San Jose, CA, USA). Cell apoptosis analysis was performed using a Flow Cytometry System (BD Bioscience, Bedford, MA, USA).

Western blot analysis
Proteins from glioma cells were homogenized in cold PBS containing 0.05% Triton X-100 and protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA). Protein samples were electrophoresed on 10% sodium
dodecyl sulfate-polyacrylamide gels (Sigma), transferred onto PVDF membranes according to standard protocols, and then blocked with 5% dried skimmed milk in TBST for at least 1 h. The membranes were incubated overnight at 4 °C with the following antibodies: anti-S100A12, anti-E-cadherin, anti-N-cadherin (1:1000, Abcam, Cambridge, MA, USA), anti-cleaved caspase 3, anti-Bcl2, anti-Bax (1:1000, Cell Signaling Technologies), and anti-GAPDH (1:1000, Abcam), and then incubated with horseradish peroxidase-conjugated secondary antibodies (1:1000, Abcam) at room temperature for 1 h after washing 3 times using TBST. Blots were washed 3 times again and developed using an enhanced chemiluminescence kit (Amersham Pharmacia Biotech). Immunoblot band quantification was calculated by means of a Bio-Rad calibrated densitometer (GS-800) using the vendor’s software (Bio-Rad Laboratories); GAPDH was used as an internal reference for analyses.

Statistical analysis
Statistical analyses were performed using the SPSS version 17.0 and GraphPad Prism version 5.0. The comparisons among multiple groups were conducted by the one-way analysis of variance (ANOVA). Pearson correlation analysis was applied for correlation analysis. Kaplan Meier analysis was used to construct the survival curves of the high expression group and the low expression group, and log rank test was used to compare the survival differences between the groups. A value of $P < 0.05$ indicated that the difference was statistically significant, and a value of $P < 0.01$ showed that the statistics were of highly significant difference.

Results
S100A12 expression is elevated in glioma tissues and is correlated with poor prognosis
To investigate the expression of S100A12 in glioma individuals, we first analyze 81 cases of glioma tissues and 6 cases of control tissues. Of the samples, 48 and 33 samples showed high and low expression of S100A12 (Table 1). The immunohistochemistry results showed that S100A12 positive staining mainly occurs in the cellular compartment of nuclei, and the staining of glioma tissues was significantly stronger than normal brain tissues (Fig. 1a). Furthermore, the data from the survival analysis (Fig. 1b) indicated that the patients with high expression of S100A12 had shorter survival time than those with low expression.

S100A12 enhances glioma proliferation in vitro
To further analysis the biological behavior of S100A12 in glioma, we examined the expression of S100A12 by western blot analysis. We found that S100A12 expression was significantly up-regulated in U251 and U87 glioma cell lines compared with those in A172, U373 and U118 glioma cell lines (Fig. 2a). Then we stably depleted its expression in U251 and U87 glioma cells with lentivirus vectors (Fig. 2a). As determined by MTT assay, both shS100A12 in U251 and U87 showed a lower growth rate than those of control groups (Fig. 2b). Similar results were displayed in colony formation assay ($P < 0.05$) (Fig. 2c and d).

S100A12 regulates glioma apoptosis in vitro
We then assessed the effect of S100A12 on the apoptosis of glioma cell lines by flow cytometry assay. The results showed the silence of S100A12 dramatically increased apoptosis rates in both U251 and U87 glioma cells with lentivirus vectors (Fig. 2a). As determined by MTT assay, both shS100A12 in U251 and U87 showed a lower growth rate than those of control groups (Fig. 2b). Similar results were displayed in colony formation assay ($P < 0.05$) (Fig. 2c and d).

S100A12 increased the invasion and migration of glioma cells
We also investigated the effect of S100A12 on glioma cells invasion and migration. As shown in Fig. 4a–d, the transwell assay displayed that the invaded and migrated U251 and U87 cells were much fewer in the shRNA S100A12 groups than in the control group ($P < 0.01$).

Table 1 Correlation between S100A12 and clinic pathologic parameters of 81 glioma patients

| Clinicopathologic parameters | Cases(N) | S100A12 expression | $P$ value |
|-----------------------------|----------|--------------------|-----------|
| Age (years)                 |          |                    |           |
| < 50                        | 29       | 13                 | 16        |
| ≥ 50                        | 52       | 20                 | 32        |
| Gender                      |          |                    |           |
| Male                        | 35       | 13                 | 22        |
| Female                      | 46       | 20                 | 26        |
| Tumor siz (cm)              |          |                    |           |
| < 2.5                       | 31       | 19                 | 12        |
| ≥ 2.5                       | 50       | 14                 | 36        |
| KPS                         |          |                    |           |
| < 80                        | 34       | 17                 | 17        |
| ≥ 80                        | 47       | 16                 | 31        |
| Grade                       |          |                    |           |
| I–II                        | 24       | 17                 | 7         |
| III–IV                      | 57       | 16                 | 41        |

Lu et al. BMC Cancer (2020) 20:261
knockdown in U251 and U87 cells, while the protein levels of N-cadherin decreased when silencing of S100A12 (Fig. 4e). Taken together, S100A12 increased the invasion and migration of glioma cells and reversed the EMT phenotype in glioma cells.

**Discussion**

Glioma is the most common central nervous system tumor and is featured by high malignancy and recurrence [1]. Although earlier studies have found novel treatment for glioma, the prognosis of this tumor remains poor [13, 14]. Thus, verification of potent therapeutic target is essential to the diagnosis and treatment of glioma.

In this study, we found that the protein expression of S100A12 was significantly increased in human glioma samples and the overexpression of S100A12 may be closely correlated with the prognosis of glioma patients. In addition, silencing of S100A12 markedly reduced the proliferation and the EMT process, whereas increased the apoptosis in two glioma cell lines, U87 and U251.

The S100 protein family has been reported in the regulation of many pathological processes, such as cell proliferation, migration and cell cycle advancement [15]. Of this subfamily, S100A12 is participated in the pathogenesis of multiple cancer-related diseases [16]. To the best of our knowledge, this study is the first to examine the expression of S100A12 in glioma patients. In this study, we found that the protein expression of S100A12 was significantly up-regulated in human glioma samples. Our study also examined the correlation between the expression of S100A12 with pathological characteristics. Our results showed that the overexpression of S100A12 was closely related with poor prognosis of glioma patients. These results indicated that S100A12 might contribute to the progression of glioma. The present study was in line with the earlier study on the expression of S100A12, which was highly correlated with the prognosis and high survival rates of oropharyngeal squamous cell carcinoma patients [10]. Huang et al. has also demonstrated that S100A12 might be serve as a new prognostic target to examine the recurrence and progression of the early stage of hepatectomy [17]. These results suggested that S100A12 might act as a biomarker in the progression of glioma patients.

In this study, silencing of S100A12 significantly down-regulated the cell viability and proliferation in two glioma cell lines. Furthermore, knockdown of S100A12 participated in the glioma cell apoptosis, which significantly increased the percentage of apoptosis rates in U87 and U251 cell lines. Moreover, silencing of S100A12 also caused the up-regulation of the protein expression of cleaved caspase 3 and Bax and down-regulation of Bcl2. These results indicated that S100A12
might contribute to the proliferation and apoptosis of glioma cells.

EMT is a process associated with the invasion and metastasis of cancer, and consequently enhances the metastasis of tumor [18]. Reduced expression of epithelial biomarker E-cadherin and elevated expression of mesenchymal biomarker N-cadherin are the most principal characteristic of EMT [19]. Cancer cells in EMT phenotype resulted in tumor metastasis and poor prognosis in patients [20]. It has been proved that glioma underwent EMT presented increased invasion and cancer metastasis, suggesting that EMT contributes to the
progression of glioma [21–23]. Our results discovered that silencing of S100A12 dramatically increased the expression of E-cadherin and reduced the expression of vimentin and N-cadherin in U87 and U251 cells. These findings indicate that knockdown of S100A12 may suppress tumor progression by inhibiting the EMT process in glioma cells.

There were also some limitations in our study. We did not overexpress S100A12 in the cells, and did not test the effect of overexpression S100A12 on cell invasion, migration and apoptosis. In addition, the mechanism of the effect of S100A12 on glioma was not deep enough. For example,
which protein does S100A12 specifically act on the EMT pathway.

**Conclusion**
Our results give novel prospect that S100A12 plays a vital role in glioma progression. S100A12 was up-regulated in glioma samples and might contributed to the prognosis of glioma patients. Moreover, silencing of S100A12 inhibits the proliferation and EMT process and promotes the apoptosis of two glioma cell lines.

**Abbreviations**
S100A12: S100 Calcium Binding Protein A12; shRNA: Short hairpin RNA; EMT: Epithelial-mesenchymal transition; PTC: Papillary thyroid carcinoma; WHO: World Health Organization; IHC: Immunohistochemistry

**Acknowledgements**
Not applicable.

**Authors’ contributions**
CH L and GY L conceived and designed the project, CH L, J L, L L, and MZ Y, performed the experiments and analyzed the data. CH L and GY L wrote the manuscript and all authors edited. GY L was responsible for research supervision and funding acquisition. All authors read and approved the manuscript.

**Funding**
The project was supported by science and technology project of Shenyang (18–014–4–03) and science and technology project of education department of Liaoning province (LFWK201705). Both funds were funded by Dr. Guangyu Li and were used for the purchase of reagents for this study.

**Availability of data and materials**
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**
The human materials were obtained with informed consent, and the study was approved by the China Medical University Ethics Committee. All patients signed an informed consent to participate in the study. The study on human specimens was approved by the China Medical University Ethics Committee Ethics Committee. Informed, written consent was obtained from all participants in the study.

**Consent for publication**
Not applicable.

**Competing interests**
The authors declare that they have no competing interests.

**Author details**
1Department of Neurosurgery, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Heping District, Shenyang City, Liaoning Province, P.R. China 110001. 2Department of Neurosurgery, Anshan Hospital...
of the First Hospital of China Medical University, No.166, Minzhu Street, Tiexi District, Anshan, Liaoning Province, P.R. China 110001.

Received: 17 October 2019 Accepted: 20 March 2020

Published online: 30 March 2020

References

1. Perry A, Wesseling P. Histologic classification of gliomas. Handb Clin Neurol. 2016;134:71–95.
2. Ghotme KA, Barreto GE, Echeverria V, et al. Gliomas: new perspectives in diagnosis, treatment and prognosis. Curr Top Med Chem. 2017;17(12):1438–47.
3. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20.
4. Ferris SP, Hofmann JW, Solomon DA, Perry A. Characterization of gliomas: from morphology to molecules. Virchows Arch. 2017;471(2):257–69.
5. Liang J, Lv X, Lu C, et al. Prognostic factors of patients with Gliomas - an analysis on 335 patients with Glioblastoma and other forms of Gliomas. BMC Cancer. 2020;20(1):135.
6. Donato R, Cannon BR, Sori G, et al. Functions of S100 proteins. Curr Mol Med. 2013;13(1):24–57.
7. Goyette J, Geczy CL. Inflammation-associated S100 proteins: new mechanisms that regulate function. Amino Acids. 2011;41(4):821–42.
8. Yang Z, Tao T, Rafferty MJ, Youssef P, Di Girolamo N, Geczy CL. Proinflammatory properties of the human S100 protein S100A12. J Leukoc Biol. 2001;69(6):986–94.
9. Thierolf M, Hagmann ML, Pfeffer M, et al. Towards a comprehensive proteome of normal and malignant human colon tissue by 2-D-LC-ESI-MS and 2-DE proteomics and identification of S100A12 as potential cancer biomarker. Proteomics Clin Appl. 2008;2(2):11–22.
10. Jin T, Zhang Z, Yang XF, Luo JS. S100A4 expression is closely linked to genesis and progression of glioma by regulating proliferation, apoptosis, migration and invasion. Asian Pac J Cancer Prev. 2015;16(7):2883–7.
11. Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro-Oncology. 2015;17(Suppl 4):iv1–iv62.
12. Wang X, Chen JX, Zhou Q, et al. Statistical report of central nervous system tumors histologically diagnosed in the Sichuan Province of China from 2008 to 2013: a West China Glioma center report. Ann Surg Oncol. 2016;23(Suppl 5):S946–53.
13. Gross SR, Sin CG, Baraduch R, Rudland PS. Joining S100 proteins and migration: for better or for worse, in sickness and in health. Cell Mol Life Sci. 2014;71(23):4493–515.
14. Katsuno Y, Lamouille S, Derynck R. TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol. 2013;25(1):76–84.
15. Bhat KP, Salazar KL, Balasubramaniyan V, et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev. 2011;25(24):2594–609.
16. Mahabir R, Tanino M, Eman sui A, et al. Sustained elevation of snail promotes gli-al mesenchymal transition after irradiation in malignant glioma. Neuro-Oncology. 2014;16(5):671–85.
17. Yan YR, Xie Q, Li F, et al. Epithelial-to-mesenchymal transition is involved in BCNU resistance in human glioma cells. Neuropathology. 2014;34(2):128–34.